HK1184686A1 - 用於治療乾眼症的地誇磷索和透明質酸或其鹽 - Google Patents

用於治療乾眼症的地誇磷索和透明質酸或其鹽

Info

Publication number
HK1184686A1
HK1184686A1 HK13112123.0A HK13112123A HK1184686A1 HK 1184686 A1 HK1184686 A1 HK 1184686A1 HK 13112123 A HK13112123 A HK 13112123A HK 1184686 A1 HK1184686 A1 HK 1184686A1
Authority
HK
Hong Kong
Prior art keywords
diquafosol
salts
treatment
hyaluronic acid
dry eye
Prior art date
Application number
HK13112123.0A
Other languages
English (en)
Inventor
優子 七條
敦義 堂田
敬 長野
雅胤 中村
明日香 阪元
Original Assignee
參天制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 參天制藥株式會社 filed Critical 參天制藥株式會社
Publication of HK1184686A1 publication Critical patent/HK1184686A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)
HK13112123.0A 2010-09-10 2013-10-28 用於治療乾眼症的地誇磷索和透明質酸或其鹽 HK1184686A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010203198 2010-09-10
PCT/JP2011/070578 WO2012033189A1 (ja) 2010-09-10 2011-09-09 Ｐ２ｙ2受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤、ドライアイの治療方法、ならびにその使用

Publications (1)

Publication Number Publication Date
HK1184686A1 true HK1184686A1 (zh) 2014-01-30

Family

ID=45810785

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13112123.0A HK1184686A1 (zh) 2010-09-10 2013-10-28 用於治療乾眼症的地誇磷索和透明質酸或其鹽

Country Status (19)

Country Link
US (1) US9006208B2 (zh)
EP (1) EP2614838B1 (zh)
JP (1) JP5956735B2 (zh)
KR (2) KR20170018462A (zh)
CN (2) CN106729718A (zh)
AU (2) AU2011299851A1 (zh)
BR (1) BR112013005438B1 (zh)
CA (1) CA2810481C (zh)
DK (1) DK2614838T3 (zh)
EA (1) EA026680B1 (zh)
ES (1) ES2569246T3 (zh)
HK (1) HK1184686A1 (zh)
MX (1) MX336944B (zh)
MY (1) MY170198A (zh)
NZ (1) NZ608202A (zh)
PL (1) PL2614838T3 (zh)
SG (1) SG188482A1 (zh)
TW (1) TWI519301B (zh)
WO (1) WO2012033189A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027736B1 (ru) * 2010-12-28 2017-08-31 Сантен Фармасьютикал Ко., Лтд. Глазной раствор, содержащий диквафозол, способ его получения и способ ингибирования образования нерастворимого осадка
EP3431092A1 (en) 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
ES2837626T3 (es) 2013-07-10 2021-07-01 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
RU2742032C2 (ru) * 2015-06-05 2021-02-01 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против сухости глаз, характеризуемое нанесением на глаза пациентов с сухостью глаз, носящих гибкие контактные линзы
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
RU2727809C2 (ru) 2015-09-24 2020-07-24 Матрикс Байолэджи Инститьют Композиции гиалуроновой кислоты с высокоэластичными свойствами и способы их применения
KR20190068575A (ko) * 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
CN109843288A (zh) 2016-10-21 2019-06-04 狮王株式会社 眼科用制剂和眼科用药
CN107096016B (zh) * 2017-06-26 2021-04-06 蒋广伟 一种缓解视力疲劳的滴液
RU2652581C1 (ru) * 2017-07-03 2018-04-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения роговично-конъюнктивального ксероза
KR102108552B1 (ko) * 2018-05-15 2020-05-08 한국세라믹기술원 히알루론산 마이크로비드의 제조 방법 및 상기 히알루론산 마이크로비드의 용도
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法
US20220054520A1 (en) 2019-02-27 2022-02-24 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer
KR102656181B1 (ko) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01115902A (ja) 1987-10-30 1989-05-09 Showa Sangyo Co Ltd ヒアルロン酸の製造法
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
AU738907C (en) 1997-02-06 2002-05-16 Merck Sharp & Dohme Corp. Dinucleotides and their use
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
NZ501696A (en) 1997-07-25 2001-08-31 Inspire Pharmaceuticals Inc Method for large-scale production of sodium and ammonium salts of di(uridine 5')-tetraphosphate
JP2003160491A (ja) 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液

Also Published As

Publication number Publication date
EA026680B1 (ru) 2017-05-31
EP2614838B1 (en) 2016-04-20
AU2017200821A1 (en) 2017-03-02
KR20130109130A (ko) 2013-10-07
US9006208B2 (en) 2015-04-14
AU2011299851A1 (en) 2013-04-04
EP2614838A1 (en) 2013-07-17
TW201216971A (en) 2012-05-01
JP2012077080A (ja) 2012-04-19
WO2012033189A1 (ja) 2012-03-15
CN106729718A (zh) 2017-05-31
KR20170018462A (ko) 2017-02-17
TWI519301B (zh) 2016-02-01
CA2810481C (en) 2018-06-19
BR112013005438A2 (pt) 2016-05-17
CA2810481A1 (en) 2012-03-15
AU2017200821B2 (en) 2018-08-30
SG188482A1 (en) 2013-04-30
MX336944B (es) 2016-02-03
CN103096929A (zh) 2013-05-08
BR112013005438B1 (pt) 2021-09-21
PL2614838T3 (pl) 2016-10-31
NZ608202A (en) 2014-08-29
DK2614838T3 (en) 2016-05-02
MX2013002677A (es) 2013-06-13
KR101707269B1 (ko) 2017-02-15
US20130172287A1 (en) 2013-07-04
EA201390364A1 (ru) 2013-08-30
MY170198A (en) 2019-07-09
ES2569246T3 (es) 2016-05-09
JP5956735B2 (ja) 2016-07-27
EP2614838A4 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
HK1184686A1 (zh) 用於治療乾眼症的地誇磷索和透明質酸或其鹽
IL261768B (en) Devices and methods for tissue treatment
EP2640461A4 (en) SYSTEMS AND METHOD FOR TREATING THE DRY EYE
HK1209788A1 (zh) 用於治療溶酶體貯積症的方法和組合物
EP2884944A4 (en) REINFORCED PLAZENTAGE WET CRANE PLANTS AND METHOD FOR THEIR PRODUCTION AND USE
AP3482A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
HK1201042A1 (zh) 用於治療干眼病的組合物
EP2800543A4 (en) DRY EYE TREATMENT SYSTEMS
EP2629736A4 (en) FABRIC TREATMENT
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
PT2810599T (pt) Sistema de estimulação elétrica para o tratamento da apneia do sono
EP2763667A4 (en) ORGANONITRO THIOETHERIC COMPOUNDS AND MEDICAL USES THEREOF
HK1210941A1 (zh) 經修飾的透明質酸衍生物及其用途
SI2576782T1 (sl) siRNA in njena uporaba v postopkih in sestavkih za zdravljenje in/ali preprečevanje očesnih stanj
EP2861244A4 (en) TREATMENT OF SLEEP APNEA
HK1196535A1 (zh) 鹽及醫藥用途
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
HK1214771A1 (zh) 用於治療皮膚病的製劑
HK1185924A1 (zh) 用於醫療器械和裝置的功能納米結構殼聚糖塗層
PL2456445T3 (pl) Środek do leczenia chorób skóry
ZA201005770B (en) The treatment of damaged skin
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
AU2012900286A0 (en) "Methods of treatment or prophylaxis"

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220909